AT Bancorp Has $470,000 Position in Alexion Pharmaceuticals, Inc. (ALXN)
AT Bancorp cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 54.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,863 shares of the biopharmaceutical company’s stock after selling 4,671 shares during the period. AT Bancorp’s holdings in Alexion Pharmaceuticals were worth $470,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the stock. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $111,000. Independent Portfolio Consultants Inc. increased its stake in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares in the last quarter. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 100 shares in the last quarter. Institutional investors own 95.14% of the company’s stock.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 138.33 on Tuesday. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.41. The stock has a 50 day moving average of $125.22 and a 200-day moving average of $122.56. The company has a market capitalization of $30.87 billion, a price-to-earnings ratio of 59.99 and a beta of 1.41.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.13 EPS. On average, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/08/at-bancorp-has-470000-position-in-alexion-pharmaceuticals-inc-alxn.html.
Several brokerages have recently commented on ALXN. UBS AG reiterated a “buy” rating and issued a $140.00 target price (down previously from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. BMO Capital Markets restated an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, May 1st. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $156.89.
In related news, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average cost of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Insiders purchased a total of 2,019,734 shares of company stock valued at $235,606,846 over the last three months. 4.35% of the stock is currently owned by insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.